期刊
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 307, 期 21, 页码 2305-2314出版社
AMER MEDICAL ASSOC
DOI: 10.1001/jama.2012.4829
关键词
-
资金
- Allergan
- UCB
- Valeant
- Ipsen
- Teva Neurosciences
- Medtronic
- Phytopharm PLC
- Solvay
- GlaxoSmithKline
- Esai Neuroscience
- Neurocrine Biosciences
- Genzyme Corporation
- ASim, a medical education company
- National Parkinson Foundation
- Michael J Fox Foundation
- book royalties
In early stages, Parkinson disease typically begins with asymmetric or unilateral motor symptoms due to combinations of mild bradykinesia, rigidity, and tremor. In most cases, with progression, signs of more generalized bradykinesia appear, which include facialmasking, reduced voice volume, and slowing of activities of daily living. In more advanced Parkinson disease, other disabling manifestations may follow, such as impaired balance, gait freezing, falls, speech disturbance, and cognitive impairment. Levodopa is the most effective medical treatment for Parkinson disease. However, motor complications uniquely related to levodopa treatment may emerge that may be difficult to manage. These include fluctuating levodopa responses and involuntary movements and postures known as dyskinesia and dystonia. Medication adjustments are usually effective, but in some cases surgical intervention with deep brain stimulation becomes necessary to alleviate motor complications. The case of Mr L, a man with an 11-year history of Parkinson disease, illustrates these emerging motor complications and the manner in which they may be managed both medically and surgically. JAMA. 2012;307(21):2305-2315 www.jama.com
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据